Since the introduction of the ICH E6 (R2) addendum, the industry has seen a rise in the implementation of a variety of risk-based monitoring (RBM) methodologies and technologies.
Since the introduction of the ICH E6 (R2) addendum, the industry has seen a rise in the implementation of a variety of risk-based monitoring (RBM) methodologies and technologies.
CluePoints is dedicated to revolutionizing clinical trials through AI, advanced statistics, and machine learning. Aligned with global regulatory guidance, our holistic risk-based approach is designed to drive positive outcomes. Ready to uncover the clues and pinpoint success in your next trial? Contact our expert team today.
